Ascendis Pharma filed an initial statement of beneficial ownership for director Albert Cha. Cha reported direct ownership of 3,730 ordinary shares. He also reported warrants exercisable for 542 ordinary shares at USD 62.17 per share and 7,500 ordinary shares at USD 108 per share. Cha also reported 1,374 restricted stock units covering ordinary shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001610717-26-000107), on March 18, 2026, and is solely responsible for the information contained therein.